Journalists

Media & Press relations

Our latest press releases

September 22, 2023

bioMérieux submits Dual 510(k) and CLIA-waiver application to FDA for the BIOFIRE^® SPOTFIRE^® Respiratory/Sore Throat (R/ST) Panel

bioMérieux, a world leader in the field of in vitro diagnostics, has submitted the BIOFIRE® SPOTFIRE® Respiratory/Sore Throat (R/ST) Panel to U.S. Food and Drug Administration (FDA) for a dual 510(k) clearance and CLIA1-waiver. This panel is already CE-marked (IVDD).

Discover more

Swipe for more

September 01, 2023

First-Half 2023 Results

Consolidated sales amounted to €1,770 million in first-half 2023, a robust growth like-for-like of 8.3% from €1,658 million in the prior year.

Read more
June 27, 2023

Jennifer Zinn appointed Executive Vice President of Clinical Operations

bioMérieux, a world leader in the field of in vitro diagnostics, announces the appointment of Jennifer Zinn as Executive Vice President of Clinical Operations effective August 1st, 2023. She succeeds Pierre Boulud, whose appointment as Chief Executive Officer was announced on June 14th.

Read more
June 14, 2023

bioMérieux evolves its governance: Alexandre Mérieux becomes Executive Chairman. Pierre Boulud is appointed Chief Executive Officer.

As of July 1st, 2023, Alexandre Mérieux will become Executive Chairman and Pierre Boulud Chief Executive Officer.

Read more